ArticleEuropean radiology2026
Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate whether cyst shrinkage in intraductal papillary mucinous neoplasm (IPMN) is paradoxically associated with a higher risk of concomitant pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND
methodsThis retrospective cohort included 1103 patients with pathologically or cytologically confirmed branch-duct or mixed-type IPMN followed for ≥ 1 year. Patients were classified by annual cyst size change rate per the 2024 Kyoto guideline thresholds: shrinkage (< 0 mm/year), stable (0 to < 2.5 mm/year), and growth (≥ 2.5 mm/year). The primary outcome was concomitant PDAC, with IPMN-derived carcinoma as a competing event. Multivariable Fine-Gray regression compared shrinkage with a pre-specified merged non-shrinkage reference; cause-specific Cox regression served as sensitivity analysis.
resultsOf 1103 patients (541 men, 562 women; mean age, 67.3 ± 9.8 years), 282 (25.6%) showed shrinkage, 728 (66.0%) remained stable, and 93 (8.4%) showed growth. Concomitant PDAC was most frequent in shrinkage (6/282, 2.1%), followed by stable (8/728, 1.1%), with no events in growth (0/93). IPMN-derived carcinoma was most frequent in growth (9/93, 9.7%). Adjusted for age, sex, initial cyst size, and main pancreatic duct diameter, shrinkage was independently associated with concomitant PDAC (subdistribution hazard ratio 4.46; 95% CI 1.62-12.30; p = 0.004); cause-specific Cox regression yielded a concordant estimate (hazard ratio 4.54; 95% CI 1.52-13.50; p = 0.007).
conclusionIn this single-center retrospective cohort, cyst shrinkage was associated with an increased incidence of concomitant PDAC, contrary to the prevailing assumption that shrinkage reflects a benign course. Given the modest number of concomitant PDAC events (n = 14), these findings are hypothesis-generating and exploratory; external validation in multicenter prospective cohorts is required before clinical surveillance practice is modified. KEY POINTS: Question Cyst shrinkage during intraductal papillary mucinous neoplasm surveillance is considered reassuring, but its association with concomitant pancreatic cancer risk remains unclear. Findings Shrinkage was paradoxically associated with higher concomitant pancreatic cancer risk (subdistribution hazard ratio 4.46); the growth group's 0% rate reflected competing risks from IPMN-derived carcinoma. Clinical relevance Radiologists should not reduce surveillance intensity for shrinking intraductal papillary mucinous neoplasm cysts, as these patients carry an elevated risk of concomitant pancreatic cancer developing independently of the monitored cyst.
Indexed as
Identifiers
42432261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.